Delving into the Latest Updates on JNJ-90301900 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

JNJ-90301900

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Locally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Lung Non-Small Cell CarcinomaNon-small cell lung cancer stage IIIB

Inactive Indication-

Originator Organization

Johnson & Johnson Enterprise Innovation, Inc.

Active Organization

Johnson & Johnson Enterprise Innovation, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Start Date06 Dec 2024

Sponsor / Collaborator

Johnson & Johnson Enterprise Innovation, Inc.

NCT04892173

/ RecruitingPhase 3

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Start Date27 Jan 2022

Sponsor / Collaborator

Johnson & Johnson Enterprise Innovation, Inc.

100 Clinical Results associated with JNJ-90301900

Login to view more data

100 Translational Medicine associated with JNJ-90301900

Login to view more data

100 Patents (Medical) associated with JNJ-90301900

Login to view more data

100 Deals associated with JNJ-90301900

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	United States	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	China	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Japan	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Austria	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Belgium	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Brazil	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Bulgaria	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Croatia	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Czechia	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	Finland	Johnson & Johnson Enterprise Innovation, Inc.	27 Jan 2022